David J. Krolikowski

David is a member of a firm wide, multidisciplinary group – Marshall Dennehey COVID-19 Task Force – created to address and support your real-time legal and business concerns in response to the coronavirus pandemic.

David’s practice focuses upon finding solutions to complex problems in high-exposure claims aided by his significant technical background in biotechnology and chemistry. This has involved him acting as national Specialty Counsel for a major insurance company, litigating birth-injury, catastrophic injury and stroke claims throughout the country. Read more about David's work with the Birth and Catastrophic Injury Litigation Practice Group here.

David also serves as the co-chair of the firm's Medical Device and Pharmaceutical Liability Practice Group, where his practice involves the representation of pharmaceutical/medical device companies in Federal Multi-District Litigation, and mass torts. He is also experienced litigating complicated environmental coverage actions, and handling complex, multi-party litigation and environmental contamination claims.

With more than 10 years of experience in research and development activities in chemistry and biology for major pharmaceutical companies, David now leverages this knowledge in defending his clients. In 1998, he graduated cum laude from Temple University where he earned a Bachelor of Science in Biology with an emphasis in Molecular Biology. While earning his degree, David worked as a Combinatorial Chemist for Rhone-Poulenc-Rorer Pharmaceuticals where he helped develop a novel activated resin for chemical library synthesis. (See Salvino, et al., under Published Works). He subsequently joined the gene therapy/cardiovascular department where he conducted extensive research into the molecular mechanism and possible treatments of cardio infarctions. (See Guo, et al. and Liu et al., under Published Works).

In 2000, David joined the immunology/oncology department of Sanofi-Aventis Pharmaceuticals where he managed a portfolio of potential drug candidates. It was during this time that David became admitted to the United States Patent and Trademark Bar and conducted strategic analysis related to potential new drug candidates. David then went to law school where in 2005, he graduated from Rutgers School of Law, in Newark, NJ. After graduation, David began to litigate product liability, medical malpractice and commercial matters, and was also involved in developing corporate compliance guidelines for a major health care corporation.